Physiological Pharmaceutics

220 Physiological Pharmaceutics74. Kimmerle R, Rolla AR. Iatrogenic Cushing’s syndrome due to dexamethasone nasaldrops. Am. J. Med. 1985; 79:535–537.75. Su XY, Po ALW. The effect of some commercially available antihistamine anddecongestant intra-nasal formulations on ciliary beat frequency. J. Clin. Pharm. Ther.1993; 18:219–222.76. Garay RP. Azalastaine: well known ciliotoxic agent? Int. J. Pharm. 1996; 136:181–183.77. Hehar SS, Mason JD, Stephen AB, Washington N, Jones NS, Jackson SJ, Bush D. twentyfour hour ambulatory nasal pH monitoring. Clin. Orolaryngol. Appl. Sci. 1999; 24:24–25.78. Gibson RE, Olanoff LS. Physicochemical determinants of nasal drug absorption. J. Cont.Rel. 1987; 6:361–366.79. Morimoto K, Yamaguchi H, Iwakura Y, Morisaka K, Ohashi Y, Nakai Y. Effects ofviscous hyaluronate-sodium solutions on the nasal absorption of vasopressin and ananalogue. Pharmaceut. Res. 1991; 8:471–474.80. Su XY, Po ALW. Surface-response study of the effect of pH and tonicity on ciliary activity.S.T.P. Pharma Sciences 1994; 4:82–85.81. Hirai S, Ikenaga R, Matsuzawa T. Nasal absorption of insulin in dogs. Diabetes 1978;27:269–299.82. Washington N, Steele RJC, Jackson SJ, Bush D, Mason J, Gill DA, Pitt K, Rawlind DA..Determination of baseline human nasal pH and the effect of intranasally administeredbuffers. Int. J. Pharmaceut. In press.83. Gizurarson S. The relevance of nasal physiology to the design of drug absorption studies.Adv. Drug Deliv. Rev. 1993; 11:329–347.